3280 Bayshore Boulevard
United States - Map
InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. The company develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, and fatal lung disease. It markets and sells pirfenidone, an orally active, anti-fibrotic agent that inhibits the synthesis of TGF-beta and TNF-alpha under the Esbriet name for the treatment of adults with mild to moderate IPF in the European Union and Canada. The companys pirfenidone has also completed three Phase III clinical trials for the treatment of IPF in the United States. The company provides pirfenidone under the Pirespa trade name for the treatment of IPF in Japan and South Korea; and is also approved for the treatment of IPF in China, India, Argentina, and Mexico. Its research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was formerly known as InterMune Pharmaceuticals, Inc. and changed its name to InterMune, Inc. in April 2001. InterMune, Inc. was founded in 1998 and is headquartered in Brisbane, California.
|InterMune, Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 7. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 6; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Daniel G. Welch ,
Chairman, Chief Exec. Officer and Pres
|Mr. John C. Hodgman B.S., M.B.A.,
Chief Financial Officer, Principal Accounting Officer and Exec. VP of Fin.
|Mr. Andrew K. W. Powell Esq.,
Exec. VP, Gen. Counsel and Corp. Sec.
|Mr. Giacomo Di Nepi ,
Exec. VP and Managing Director of Europe
|Mr. Sean P. Nolan ,
Chief Bus. Officer and Exec. VP
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|